Allianz Asset Management GmbH Has $8.09 Million Stake in Insmed, Inc. $INSM

Allianz Asset Management GmbH increased its holdings in Insmed, Inc. (NASDAQ:INSM) by 6.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,422 shares of the biopharmaceutical company’s stock after buying an additional 5,138 shares during the period. Allianz Asset Management GmbH’s holdings in Insmed were worth $8,094,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock valued at $1,393,675,000 after buying an additional 49,149 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Insmed by 1.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock valued at $985,938,000 after buying an additional 219,131 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in Insmed by 109.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after purchasing an additional 1,799,382 shares in the last quarter. Alliancebernstein L.P. raised its position in Insmed by 2.5% during the first quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company’s stock valued at $184,890,000 after purchasing an additional 59,952 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Insmed by 3.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,602,655 shares of the biopharmaceutical company’s stock valued at $122,267,000 after purchasing an additional 56,048 shares in the last quarter.

Insmed Stock Down 1.5%

Shares of NASDAQ:INSM opened at $165.31 on Wednesday. The company has a fifty day moving average of $145.35 and a 200-day moving average of $106.37. The company has a market capitalization of $34.94 billion, a PE ratio of -28.95 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $168.21.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm’s quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter last year, the company posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In related news, Director Melvin Md Sharoky sold 10,000 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director owned 262,675 shares of the company’s stock, valued at $38,190,318.25. The trade was a 3.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO William Lewis sold 6,865 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $128.40, for a total transaction of $881,466.00. Following the completion of the sale, the chief executive officer directly owned 233,924 shares in the company, valued at approximately $30,035,841.60. This represents a 2.85% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 152,657 shares of company stock valued at $21,442,198. 3.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on INSM. Mizuho boosted their price objective on shares of Insmed from $130.00 to $165.00 and gave the company an “outperform” rating in a research report on Wednesday, August 13th. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 20th. Truist Financial boosted their price objective on shares of Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. TD Cowen boosted their price objective on shares of Insmed from $154.00 to $193.00 and gave the company a “buy” rating in a research report on Thursday, October 2nd. Finally, Jefferies Financial Group boosted their price objective on shares of Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $152.88.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.